TY - JOUR
T1 - Targeting RAGE in sepsis
AU - van Zoelen, Marieke A. D.
AU - van der Poll, Tom
PY - 2008
Y1 - 2008
N2 - The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena
AB - The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena
U2 - https://doi.org/10.1186/cc6187
DO - https://doi.org/10.1186/cc6187
M3 - Editorial
C2 - 18254937
SN - 1364-8535
VL - 12
SP - 103
JO - Critical care (London, England)
JF - Critical care (London, England)
IS - 1
ER -